In conclusion, this study presented a mutational landscape of actionable genes in CRC, validating the prognostic role of genomic alterations in TP53, BRAF, ATM, KRAS, and FBXW7 as well as MSI status. This evidence concerns the gene ATM and colorectal carcinoma.